Grifols, S.A Debt to Equity Ratio 2012-2020 | GRFS

Current and historical debt to equity ratio values for Grifols, S.A (GRFS) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Grifols, S.A debt/equity for the three months ending March 31, 2020 was 0.95.
Grifols, S.A Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2020-03-31 $7.57B $7.95B 0.95
2019-06-30 $7.58B $5.49B 1.38
2018-06-30 $7.20B $4.74B 1.52
2017-06-30 $6.65B $3.94B 1.69
2017-03-31 $6.75B $4.07B 1.66
2016-12-31 $5.21B $4.13B 1.26
2016-09-30 $5.01B $3.94B 1.27
2016-06-30 $5.10B $3.86B 1.32
2016-03-31 $4.87B $3.64B 1.34
2015-12-31 $5.11B $3.67B 1.39
2015-09-30 $4.89B $3.56B 1.37
2015-06-30 $4.90B $3.40B 1.44
2015-03-31 $5.22B $3.54B 1.47
2014-12-31 $5.52B $3.54B 1.56
2014-09-30 $5.35B $3.37B 1.59
2014-06-30 $5.15B $3.07B 1.68
2014-03-31 $5.13B $3.05B 1.68
2013-12-31 $3.39B $2.80B 1.21
2013-09-30 $3.48B $2.61B 1.33
2013-06-30 $3.52B $2.54B 1.39
2013-03-31 $3.62B $2.59B 1.40
2012-12-31 $3.46B $2.42B 1.43
2012-09-30 $3.30B $2.32B 1.42
2012-06-30 $3.47B $2.36B 1.47
2012-03-31 $3.36B $2.21B 1.52
2011-12-31 $3.91B $2.32B 1.69
2011-09-30 $4.02B $2.26B 1.78
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $12.555B $5.711B
Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $65.157B 36.98
Takeda Pharmaceutical (TAK) Japan $55.614B 9.75
Astellas Pharma (ALPMY) Japan $30.217B 15.31
Eisai (ESALY) Japan $23.722B 20.56
UCB SA (UCBJF) Belgium $22.504B 0.00
Merck (MKGAF) Germany $15.186B 19.92
Neurocrine Biosciences (NBIX) United States $11.686B 54.01
Catalent (CTLT) United States $11.365B 43.93
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $9.945B 0.00
Ono Pharmaceutical (OPHLF) Japan $9.254B 0.00
Ionis Pharmaceuticals (IONS) United States $8.387B 44.59
IPSEN SA ADR (IPSEY) France $6.994B 0.00
Orion OYJ (ORINY) Finland $6.766B 30.32
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $6.676B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $6.067B 9.71
United Therapeutics (UTHR) United States $5.325B 10.09
STADA ARZNEIMI (STDAF) Germany $4.916B 0.00
Arrowhead Pharmaceuticals (ARWR) United States $4.494B 490.67
Nektar Therapeutics (NKTR) United States $4.174B 0.00
Evotec AG (EVTCY) Germany $4.100B 110.63
Hypermarcas (HYPMY) Brazil $3.989B 12.13
FibroGen (FGEN) United States $3.754B 0.00
ChemoCentryx (CCXI) United States $3.597B 0.00
PTC Therapeutics (PTCT) United States $3.379B 0.00
Taro Pharmaceutical Industries (TARO) Israel $2.582B 10.61
Sage Therapeutics (SAGE) United States $2.251B 0.00
Pacira BioSciences (PCRX) United States $2.238B 45.81
Cronos Group (CRON) Canada $2.132B 61.10
Corcept Therapeutics (CORT) United States $1.959B 19.42
Xencor (XNCR) United States $1.821B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.796B 0.00
Indivior (INVVY) United States $1.764B 21.89
Akebia Therapeutics (AKBA) United States $1.680B 0.00
Ironwood Pharmaceuticals (IRWD) United States $1.621B 12.40
Zogenix (ZGNX) United States $1.609B 0.00
USANA Health Sciences (USNA) United States $1.558B 15.98
Heron Therapeutics (HRTX) United States $1.454B 0.00
Portola Pharmaceuticals (PTLA) United States $1.415B 0.00
Esperion Therapeutics (ESPR) United States $1.412B 0.00
Karyopharm Therapeutics (KPTI) United States $1.408B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $1.389B 14.97
Theravance Biopharma (TBPH) Cayman Islands $1.303B 0.00
CLINIGEN GP (CLIGF) United Kingdom $1.250B 0.00
Translate Bio (TBIO) United States $1.098B 0.00
Enanta Pharmaceuticals (ENTA) United States $1.025B 45.76
Tilray (TLRY) Canada $0.875B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.866B 0.00
ImmunoGen (IMGN) United States $0.828B 0.00
Endo (ENDP) Ireland $0.806B 1.25
Trillium Therapeutics (TRIL) Canada $0.676B 0.00
Aerie Pharmaceuticals (AERI) United States $0.672B 0.00
Radius Health (RDUS) United States $0.649B 0.00
Molecular Templates (MTEM) United States $0.619B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.608B 0.00
Ardelyx (ARDX) United States $0.607B 0.00
Collegium Pharmaceutical (COLL) United States $0.596B 0.00
VAXART, INC (VXRT) United States $0.593B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.580B 0.00
Flexion Therapeutics (FLXN) United States $0.503B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.498B 12.05
Innate Pharma SA (IPHYF) France $0.476B 0.00
Siga Technologies (SIGA) United States $0.476B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.465B 18.14
MEI Pharma (MEIP) United States $0.453B 0.00
Ocular Therapeutix (OCUL) United States $0.440B 0.00
DURECT (DRRX) United States $0.440B 0.00
Harpoon Therapeutics (HARP) United States $0.437B 0.00
Spectrum Pharmaceuticals (SPPI) United States $0.430B 0.00
Organogenesis Holdings (ORGO) United States $0.398B 0.00
Calithera Biosciences (CALA) United States $0.369B 0.00
TherapeuticsMD (TXMD) United States $0.353B 0.00
OptiNose (OPTN) United States $0.326B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.300B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.298B 0.00
Lannett Co Inc (LCI) United States $0.285B 6.26
Concert Pharmaceuticals (CNCE) United States $0.285B 0.00
PROFOUND MEDICL (PROF) Canada $0.283B 0.00
Oasmia Pharmaceutical AB (OASMY) Sweden $0.262B 0.00
CASI Pharmaceuticals (CASI) United States $0.249B 0.00
Redhill Biopharma (RDHL) Israel $0.240B 0.00
Rafael Holdings (RFL) United States $0.233B 0.00
Jounce Therapeutics (JNCE) United States $0.227B 5.43
Taiwan Liposome (TLC) Taiwan $0.217B 0.00
KalVista Pharmaceuticals (KALV) United States $0.216B 0.00
IMV INC (IMV) Canada $0.178B 0.00
Nivalis Therapeutics (ALPN) United States $0.177B 0.00
Nature's Sunshine Products (NATR) United States $0.175B 23.08
Aquestive Therapeutics (AQST) United States $0.159B 0.00
Matinas Biopharma Holdings (MTNB) United States $0.154B 0.00
Altimmune (ALT) United States $0.154B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.123B 0.00
Champions Oncology (CSBR) United States $0.114B 0.00
Recro Pharma (REPH) United States $0.111B 0.00
Aptorum Group (APM) Hong Kong, SAR China $0.110B 0.00
Otonomy (OTIC) United States $0.105B 0.00
Xeris Pharmaceuticals (XERS) United States $0.103B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.103B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.102B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.101B 0.00
Onconova Therapeutics (ONTX) United States $0.099B 0.00
ALLERGY THERAPT (AGYTF) United Kingdom $0.095B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.095B 0.00
MediWound (MDWD) Israel $0.092B 0.00
Sundial Growers (SNDL) Canada $0.086B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.086B 0.00
CTI BioPharma (CTIC) United States $0.085B 0.00
Biomerica (BMRA) United States $0.081B 0.00
Hemispherx BioPharma (AIM) United States $0.080B 0.00
SCYNEXIS (SCYX) United States $0.073B 0.00
Heat Biologics (HTBX) United States $0.072B 0.00
Aclaris Therapeutics (ACRS) United States $0.069B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.067B 0.00
CV Sciences (CVSI) United States $0.061B 0.00
Lipocine (LPCN) United States $0.059B 0.00
RENEURON GP (RNUGF) United Kingdom $0.057B 0.00
Infinity Pharmaceuticals (INFI) United States $0.051B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.051B 30.27
PolarityTE (PTE) United States $0.049B 0.00
Addex Therapeutics (ADXN) Switzerland $0.048B 0.00
Natural Alternatives (NAII) United States $0.048B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.043B 0.00
Forward Pharma (FWP) Denmark $0.043B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.042B 0.00
GTx (ONCT) United States $0.042B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.041B 0.00
Novan (NOVN) United States $0.040B 0.00
Mannatechorporated (MTEX) United States $0.040B 7.58
IsoRay (ISR) United States $0.038B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.038B 81.09
Neos Therapeutics (NEOS) United States $0.035B 0.00
NovaBay Pharmaceuticals (NBY) United States $0.033B 0.00
AgeX Therapeutics (AGE) United States $0.033B 0.00
ElectroCore (ECOR) United States $0.030B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.029B 0.00
Jaguar Animal Health (JAGX) United States $0.028B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.022B 0.00
India Globalization Capital (IGC) United States $0.022B 0.00
Bio-Path Holdings (BPTH) United States $0.019B 0.00
Flex Pharma (SLRX) United States $0.019B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.019B 0.00
Iterum Therapeutics (ITRM) Ireland $0.017B 0.00
Can-Fite Biopharma (CANF) Israel $0.017B 0.00
ProPhase Labs (PRPH) United States $0.016B 0.00
Regulus Therapeutics (RGLS) United States $0.015B 0.00
Cyanotech (CYAN) United States $0.015B 35.29
Shineco (TYHT) China $0.014B 0.00
China SXT Pharmaceuticals (SXTC) China $0.014B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.012B 0.00
RXi Pharmaceuticals (PHIO) United States $0.010B 0.00
Vical (BBI) United States $0.010B 0.00
HANCOCK JAFFE (HJLI) United States $0.009B 0.00
Midatech Pharma (MTP) United Kingdom $0.009B 0.00
Cytori Therapeutics Inc (PSTV) United States $0.009B 0.00
Xenetic Biosciences (XBIO) United States $0.007B 0.00
CannTrust Holdings (CTST) Canada $0.000B 0.00